Progressive Care Reaches Record $1.3 Million in Ph
Post# of 1525
Posted On: 01/01/2016 8:20:34 PM
Progressive Care Reaches Record $1.3 Million in Pharmacy Revenues in November
MIAMI, FL--(Marketwired - December 14, 2015) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary PharmCo, LLC, a South Florida provider of prescription pharmaceuticals specializing in health practice risk management, the sale of anti-retroviral medications and related medication therapy management, the sale and rental of durable medical equipment ("DME"
and the supply of prescription medications to long term care facilities, announces record November pharmacy revenues.
The pharmacy filled approximately 15,000 prescriptions during the month of November, which is nearly a 30% increase over the same month last year. Historically, due to the open enrollment window, physicians undergo major changes to their patient base resulting decreases in prescriptions written. However, PharmCo grossed approximately $1.3 million in net revenues for the month despite the lower prescription count. The compounding department continues to drive strong revenue growth.
"The company remains focused on creating earnings growth," stated Shital Parikh Mars, COO. "Our strategic marketing campaigns and strong forecasting methods have allowed us to withstand dips and changes in the industry. As always, we plan to close out the year stronger than ever and deliver the value that shareholders have come to expect from us."
About Progressive Care
Progressive Care, Inc. (OTC PINK: RXMD), through its subsidiary PharmCo, LLC, is a South Florida provider of prescription pharmaceuticals specializing in health practice risk management, the sale of anti-retroviral medications and related medication therapy management, the sale and rental of durable medical equipment and the supply of prescription medications to long term care facilities.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements
Copyright © 2015 Marketwired. All Rights Reserved
MIAMI, FL--(Marketwired - December 14, 2015) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary PharmCo, LLC, a South Florida provider of prescription pharmaceuticals specializing in health practice risk management, the sale of anti-retroviral medications and related medication therapy management, the sale and rental of durable medical equipment ("DME"
and the supply of prescription medications to long term care facilities, announces record November pharmacy revenues. The pharmacy filled approximately 15,000 prescriptions during the month of November, which is nearly a 30% increase over the same month last year. Historically, due to the open enrollment window, physicians undergo major changes to their patient base resulting decreases in prescriptions written. However, PharmCo grossed approximately $1.3 million in net revenues for the month despite the lower prescription count. The compounding department continues to drive strong revenue growth.
"The company remains focused on creating earnings growth," stated Shital Parikh Mars, COO. "Our strategic marketing campaigns and strong forecasting methods have allowed us to withstand dips and changes in the industry. As always, we plan to close out the year stronger than ever and deliver the value that shareholders have come to expect from us."
About Progressive Care
Progressive Care, Inc. (OTC PINK: RXMD), through its subsidiary PharmCo, LLC, is a South Florida provider of prescription pharmaceuticals specializing in health practice risk management, the sale of anti-retroviral medications and related medication therapy management, the sale and rental of durable medical equipment and the supply of prescription medications to long term care facilities.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements
Copyright © 2015 Marketwired. All Rights Reserved
(0)
(0)